Recursion CEO outlines AI drug discovery strategy in Morgan Stanley webcast

FierceBiotechCardiovascular-focused Kardigan plans to bring in cozy $320M haul from upcoming IPO

FierceBiotechCaribou boosts case that off-the-shelf CAR-T matches autologous drugs ahead of phase 3

CellDNA repair drives cisplatin-induced neuronal death

CellLong-term reversal of Duchenne muscular dystrophy via circular arRNA-guided exon skipping in monkeys and humans

CellPersistent and transient senescent cells contribute to brain-barrier development

CellContinuous modeling of primate embryogenesis from totipotency to early organogenesis

CellRNA structure programs endogenous ADAR for precise and efficient editing

FierceBiotech‘I’m a lot more optimistic today’: Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEO

FierceBiotechTakeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown

Endpoints NewsTakeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3

Endpoints NewsNeion Bio raises $23M Series A to make proteins from chicken eggs

BioPharma DiveTakeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test